Why This Investor Is Selling His Seagen Shares

Having fallen more than 22% over the last month, Seagen Inc SGEN shares are now trading down about 15% year-to-date. With Seagen stock seemingly stuck in a downtrend, Virtus Investment Partners' Joe Terranova decided to cut his position.

"Biotech, in this environment, will continue to struggle," Terranova said Monday on CNBC's "Fast Money Halftime Report."

Seagen is a biotech firm that develops and commercializes therapies to treat cancers. The stock is trading with a "very high valuation" and currently, longer-duration assets are being corrected, Terranova said. 

Seagen is currently trading with a 15.788 price-to-sales ratio, according to data from Benzinga Pro.

From Last Month: Notable Seagen Insider Trades $1.2M In Company Stock

Terranova told CNBC he has risk management disciplines in place and current market conditions put him in a position where he needed to exit the stock.

"Seagen is not proving to be a profitable holding for me," he said.

Seagen is set to highlight new data in advanced breast cancer at the San Antonio Breast Cancer Symposium Dec. 7-10.

SGEN Price Action: Seagen has traded as high as $202.60 and as low as $133.20 over a 52-week period.

The stock was down 2.7% at $146.64 Monday afternoon.

Photo: jarmoluk from Pixabay.

Market News and Data brought to you by Benzinga APIs
Posted In: BiotechShort IdeasMediaTrading IdeasGeneralJoe Terranovawhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!